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Background: Matrix metalloproteinase 7 (MMP-7) promotes tumor invasion and metastasis in several cancers.
However, its role in lung cancer progression is understudied. In this study, we investigated the correlation between
MMP-7 expression and lung cancer pathology.
Methods: We searched the databases PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, China
BioMedicine (CBM) and China National Knowledge Infrastructure (CNKI) for scientific literature relevant to MMP-7
and lung cancer. Carefully selected studies were pooled and ORs with 95% CI were calculated. Subgroup analyses
and publication bias were analyzed to understand the retrieved data in greater detail. Version 12.0 STATA software
was used for statistical analysis.
Results: We retrieved a total of 121 studies through database searches. Finally, 14 cohort studies satisfied our
inclusion/exclusion criteria, and these 14 studies, published between 2004 and 2012, were selected for meta-analysis
to understand the influence of MMP-7 expression in lung cancer progression. Our results showed consistent
differences in MMP-7 expression when comparisons were made between TNM I-II versus III-IV (OR = 1.82, 95% CI:
1.19 to 2.78, P = 0.006); histologic grade 1 to 2 versus 3 to 4 (OR = 1.67, 95% CI: 1.14 to 2.42, P = 0.008); and lymph
node-negative versus lymph node-positive samples (OR = 2.81, 95% CI: 1.73 to 4.58, P <0.001), with significantly
higher MMP-7 expression levels found in the more advanced stages. Subgroup analysis showed that age was not
the factor influencing the associations between histologic grade, LN metastasis and MMP-7 expression in lung
cancer patients, as both under 60 and over 60 age groups showed strong correlations (all P <0.05). However,
when TNM staging was analyzed for its association with MMP-7 expression, only patients under age 60 showed a
statistically significant correlation.
Conclusions: Our meta-analysis results revealed that MMP-7 overexpression is associated with advanced TNM and
histological grades, and is linked to aggressive LN metastasis in lung cancer patients; thus MMP-7 is a useful
biomarker to assess the disease status in lung cancers.
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Lung cancer is ranked at the top of all cancer-related
deaths worldwide due to its high incidence rates, rapid
malignant progression and current lack of specific and
effective treatment strategies for lung cancers [1-3]. The
clinical signs and symptoms of lung cancer present as
persistent coughing, coughing up blood, wheezing, weight
loss, fever, chest pain, bone pain, superior vena cava
obstruction and difficulty in swallowing [4,5]. Lung* Correspondence: zhangyijie453@126.com
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unless otherwise stated.cancer remains the leading malignancy in males and is
the second leading cancer in females among all cancers
worldwide, and urban populations have higher morbidity
rates than rural, due to air pollution [6,7]. Lung cancer is
associated with multiple risk factors, among which
cigarette smoking is at the top, and other factors such
as age, sex, excessive alcohol consumption, and air pol-
lution are also major contributing factors in lung can-
cer [8,9]. Despite our expanding knowledge of cancers
and the latest improvements in clinical diagnosis and
treatment, lung cancer patients have poor prognosis,
with 5-year survival rates at only 9 to 20%. Thus, thereis is an Open Access article distributed under the terms of the Creative
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value of factors relevant to lung cancer progression
[10,11]. Matrix metalloproteinase 7 (MMP-7) is one of
the leading biomarkers in several cancers and has
recently generated interest for its potential applications in
lung cancer settings [12,13].
MMP-7 is the smallest of the matrix metalloprotein-
ases (MMPs) in size, with 28 kDa latent pro-form, and
the mature form being 19 kDa [14]. MMP-7 is composed
of a five-stranded β-sheet and three α-helices, with zinc-
containing active domain, and other zinc and calcium ions
necessary for structural stability [15]. As a typical member
of the MMP family, MMP-7 has the ability to degrade
extracellular matrix (ECM) components, such as elastin,
type IV collagen, fibronectin, vitronectin, aggrecan and
proteoglycans [16]. MMP-7 also exhibits proteinase ac-
tivities against additional targets resulting in release of
growth factors such as epidermal growth factor recep-
tor (EGFR), heparin binding epidermal growth factor
(HB-EGF) from the extracellular matrix, and in ectodo-
main shedding of cell-surface molecules, including Fas
ligand and E-cadherin [17]. These activities of MMP-7
have important biological consequences relevant to
tumor progression and metastasis. Not surprisingly,
MMP-7 is linked to the disease progression in oral
squamous cell carcinoma, prostate cancer, pancreatic
cancer, colon cancer, breast cancer and non-small cell
lung cancer [18-23]. A few studies have reported that
MMP-7 shows a great promise as a biomarker to assess
lung cancer proliferation, differentiation and metastasis
[24,25]. However, there are also studies with contrary
results [26,27]. Thus, we performed a systematic meta-
analysis to evaluate the link between MMP-7 protein
expression and the pathological features in lung cancer.
Methods
Data sources and keywords
We searched for studies published prior to 1 July 2014
that assessed the association between MMP-7 protein
expression and the pathological features of lung cancer.
Relevant studies were retrieved through information
available from computerized databases such as PubMed,
Embase, Web of Science, Cochrane Library, CISCOM,
CINAHL, China BioMedicine (CBM) and China National
Knowledge Infrastructure (CNKI), utilizing selected com-
mon keywords (‘matrix metalloproteinase 7’ or ‘MMP7
protein, human’ or ‘matrix metalloproteinase-7’ or ‘MMP-7’
or ‘MMP 7’ or ‘matrilysin’) and (‘lung neoplasms’ or ‘lung
cancer’ or ‘lung carcinoma’ or ‘pulmonary carcinoma’ or
‘pulmonary cancer’ or ‘pulmonary neoplasms’ or ‘lung
tumor’ or ‘pulmonary tumor’). No restriction was set to
the language of the article. We also further manually
scanned the bibliographies of relevant articles to identify
additional potential relevant papers. If selected studiescontained unclear data, the first authors were contacted
for clarifications.Selection criteria
Published studies that were retrieved through database
searches were further screened to meet the following
selection criteria: (1) papers had to include lung cancer
patients with different TNM stage, histologic grade,
histology and LN metastasis status; (2) papers had to
be human-associated clinical cohort studies that focused
on the role of MMP-7 protein expression in the patho-
logical features of lung cancer; (3) papers had to provide
available data for MMP-7 protein expression; (4) papers
had to report the adjusted odd ratios (ORs) at 95% confi-
dence intervals (CI) for MMP-7 protein expression; and
(5) papers had to report a minimum number of samples
greater than 30. However, when the extracted studies had
overlapping subjects of more than 50% in two or more
papers, we selected the study that was the most compre-
hensive, and only the latest or most complete study was
included when the extracted studies were published by
the same authors.Data extraction
In order to reduce bias and enhance confidence in the
data, two investigators separately extracted information
from the retrieved papers according to the selection cri-
teria and arrived at a consensus on all the items through
discussion and reexamination. The following relevant data
were extracted from eligible studies prospectively for the
final meta-analysis: surname of first author, time of publi-
cation, ethnicity and country of publication, study type,
study design, sample size, age and sex of subjects, source
of samples, detection method for MMP-7 protein expres-
sion, MMP-7 protein expression in cases with different
TNM stage, histologic grade, and histology or LN metas-
tasis status. All authors approved the studies for their final
inclusion in the meta-analysis.Quality assessment
To ensure that the study was high quality, two authors used
a set of predefined criteria based on the Newcastle-Ottawa
Scale (NOS) criteria to evaluate the studies independently
[28]. The NOS criteria is scored based on three aspects:
(1) subject selection: 0 to 4; (2) comparability of subject: 0
to 2; and (3) clinical outcome: 0 to 3. Total NOS scores
range from 0 (lowest) to 9 (highest). According to the
NOS scores, the included studies were classified into
two levels: low quality (0 to 6), and high quality (7 to 9).
Discrepancies on NOS scores of the enrolled articles
were resolved by discussion and consultation with an
additional reviewer.
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To calculate the effect size for each study, the summary
ORs with 95% CI were used for TNM stage III-IV versus
TNM stage I-II, histologic grade 1 to 2 versus histologic
grade 3 to 4, adenocarcinoma versus squamous cell car-
cinoma, and with lymph node (LN) metastasis versus
without LN metastasis categories of MMP-7 protein ex-
pression, using Z test. In order to supply quantitative
evidence of all selected studies and minimize the variance
of the summary ORs with 95% CI, we conducted the
current statistical meta-analysis by utilizing a random-
effects model (DerSimonian and Laird method) or a fixed
effects model (Mantel-Haenszel method) of individual
study results under the situation where data from inde-
pendent studies were combined. A random effects model
was applied when heterogeneity existed among studies,
while a fixed effects model was applied when there was
no statistical heterogeneity. The heterogeneity across the
selected studies was evaluated by Cochran’s Q-statistic
(P <0.05 was regarded as statistically significant) [29].
Due to low statistical power of Cochran’s Q-statistic, I2
test (0%, no heterogeneity; 100%, maximal heterogen-
eity) was also used to measure heterogeneity between
studies [30]. The meta-regression and subgroup meta-
analysis by detection method and country was conducted
to explore potential effect modification. The one-way sen-
sitivity analysis was performed through deleting single
studies in our meta-analysis one by one to reflect the in-
fluence of the individual data set to the pooled ORs. The
funnel plot was constructed to assess publication bias that
might affect the validity of the estimates. The symmetry of
the funnel plot was further assessed by Egger’s linear re-
gression test [31]. To make sure that the results are cred-
ible and accurate, two investigators independently input
all information in the STATA software, version 12.0 (Stata




A flow chart of the study selection process is displayed in
Figure 1. A total of 121 published studies were initially
retrieved by electronic database searches, followed by
manual search. We excluded duplicates (n = 2), letters,
reviews or meta-analysis (n = 16), nonhuman studies
(n = 27), studies not related to research topics (n = 30),
noncase-controlled or cohort studies (n = 7), studies not
relevant to MMP-7 protein studies (n = 10), studies not
relevant to lung cancer (n = 13) and studies that did
not supply enough information (n =2). Finally, a total of
14 cohort studies, published between 2004 and 2012, pro-
vided the necessary information about the correlation of
protein expression of MMP-7 with the pathological fea-
tures of lung cancer [17,24,25,27,32-41]. Demographicinformation on adult subjects with lung cancer, and
other characteristics and methodological quality was
extracted from the selected studies for our analysis.
Thirteen studies were performed on Asian populations,
and one study was on Caucasians. The 14 studies con-
tained a total of 1,599 lung cancer patients with differ-
ent TNM stages, histological grades, or LN metastasis
status. The countries where the studies were performed
were China (n = 12), Japan (n = 1), and Finland (n = 1).
MMP-7 data in our present meta-analysis were all ob-
tained from patient tissues. MMP-7 detection methods
included streptavidin-peroxidase (SP, n = 8), and Non-SP
(n = 6) including streptavidin-biotin peroxidase com-
plex (SABC), SLAB, avidin-biotin-peroxidase complex
(ABC) and APAAP. The baseline characteristics of the
enrolled studies are listed in Table 1.
Association of matrix metalloproteinase 7 protein
expression with pathological features of lung cancer
As shown in Figure 2, the major findings of the present
meta-analysis revealed a significantly higher MMP-7
protein expression in lung cancer patients with TNM
stage III-IV compared to patients with TNM stage I-II
(OR = 1.82, 95% CI: 1.19-2.78, P = 0.006). However,
Figure 2 also suggested MMP-7 protein expression in
lung cancer patients with histologic grade 3 to 4 (3:
moderately differentiated; 4: highly differentiated) was
lower than that in patients with histologic grade 1 to 2
(1: undifferentiated; 2: poorly differentiated) (OR = 1.67,
95% CI: 1.14 to 2.42, P = 0.008). We did not detect a statis-
tically significant difference in MMP-7 protein expression
between adenocarcinoma patients and squamous cell
carcinoma patients (P = 0.273), and MMP-7 protein ex-
pression in lung cancer patients with LN metastasis
was significantly higher than that in patients without
LN metastasis (OR = 2.81, 95% CI: 1.73-4.58, P <0.001).
Subgroup analysis based on age showed that higher
MMP-7 protein expression was detected in lung cancer
patients with TNM stage III-IV compared to TNM stage
I-II in all patients under age 60 (OR = 2.43, 95% CI: 1.53
to 3.87, P <0.001), while there was no such statistically
significant differences in patients over 60 years age
(OR = 1.71, 95% CI = 0.92-3.16, P = 0.09). MMP-7 pro-
tein expression in lung cancer with histologic grade 3 to 4
was remarkably higher than histologic grade 1 to 2,
which was not influenced by age (Age <60: OR = 1.63,
95% CI = 1.08 to 2.47, P = 0.021; Age ≥ 60: OR = 1.56,
95% CI = 1.02-2.38, P = 0.041) (as shown in Figure 3). It
is also clear from Figure 3, based on histology, that
MMP-7 protein expression in adenocarcinoma patients
was significantly higher than squamous cell carcinoma pa-
tients, in patients under age 60 (OR = 1.59, 95% CI = 1.05
to 2.40, P = 0.028), but this difference was not statistically
significant in patients over 60 years age (OR = 1.14, 95%
Figure 1 Flow chart of study selection procedure. Fourteen studies were included in this meta-analysis.
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expression in lung cancer patients with lymph node metas-
tasis was significantly higher than in lung cancer patients
without lymphatic metastasis, which was not influenced by
age (positive: OR = 3.89, 95% CI = 2.27 to 6.67, P <0.001;Table 1 Baseline characteristics of the enrolled studies
First author Year Country Tumor Sex (M/F
Wang JX [39] 2012 China 56 41/15
Yamamoto T [27] 2012 Japan 78 54/24
Bao WH [33] 2011 China 60 42/18
Ban YY [32] 2011 China 80 52/28
Zhang Y [41] 2009 China 70 44/26
Song BH [38] 2009 China 66 52/14
Li JF [35] 2009 China 30 19/11
Xing YH [40] 2008 China 58 44/14
Liu H [24] 2008 China 159 118/41
Liu D [17] 2007 Japan 147 99/48
Leinonen T [25] 2006 Finland 212 192/20
Hsu CP [34] 2006 China 57 49/8
Mei TH [37] 2004 China 74 45/29
Lin TS [36] 2004 China 452 361/91
F, female; M, male; NOS, Newcastle-Ottawa Scale; SP, streptavidin-peroxidase.negative: OR = 1.86, 95% CI = 1.31 to 2.64, P <0.001)
(Figure 3).
Further subgroup analysis based on MMP-7 detection
methods revealed that MMP-7 protein expression in
lung cancer patients with TNM stage III-IV expressed) Age (years) Sample Method NOS score
58 (34 to 75) Tissue SP 6
64.7 ± 10.8 Tissue SP 7
60 (36 to 73) Tissue SP 6
60 935 to 82) Tissue SP 7
65 (48 to 79) Tissue SP 7
59 Tissue SP 6
56 (40 to 82) Tissue SP 6
58 (36 to 78) Tissue Non-SP 6
54 (39 to 74) Tissue Non-SP 8
- Tissue Non-SP 7
63 (42 to 78) Tissue Non-SP 8
66.3 (36 to 84) Tissue Non-SP 6
54 (26 to 72) Tissue SP 7
- Tissue Non-SP 8
Figure 2 Forest plots for the association between matrix metalloproteinase 7 (MMP-7) protein expression and the pathological
characteristics of lung carcinoma.
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SP (OR = 2.52, 95% CI: 1.57 to 4.03, P <0.001), while the
difference of MMP-7 protein expression between lung
cancer patients with TNM stage III-IV and patients with
TNM stage I-II showed no statistical significance by
using Non-SP (P = 0.519), as shown in Figure 3. A lower
MMP-7 protein expression was detected by using SP in
lung cancer patients with histologic grade 3 to 4 than
that in patients with histologic grade 1 to 2 (OR = 2.02,
95% CI: 1.17 to 3.50, P = 0.011), while the difference of
MMP-7 protein expression by using Non-SP between
lung cancer patients with histologic grade 3 to 4 and
patients with histologic grade 1 to 2 showed no statis-
tical significance (P = 0.251) (as seen in Figure 3). The
difference of MMP-7 protein expression between adeno-
carcinoma patients and squamous cell carcinoma patients
has no obvious statistical significance whether by using SP
or Non-SP (both P >0.05) (as shown in Figure 3). Fur-
thermore, irrespective of SP or Non-SP, MMP-7 protein
expression in lung cancer patients with LN metastasis
was higher than patients without LN metastasis (both
P <0.05), as shown in the Figure 3 subgroup analysis by
detection method.Sensitivity analysis and publication bias
A sensitivity analysis was carried out to evaluate whether
the present meta-analysis is stable. Each study enrolled
in our meta-analysis was evaluated individually to reflect
its effect on the significance of pooled ORs. The overall
statistical significance did not change when any single
study was omitted. Therefore, the current meta-analysis
data is relatively stable and credible (Figure 4). The
graphical funnel plots of those 14 studies for TNM stage
III-IV versus TNM stage I-II for MMP-7 protein expres-
sion demonstrated evidence of obvious asymmetry, and
Egger’s test displayed statistical evidence for publication
bias (P <0.05) (Figure 5). However, the graphical funnel
plots of the 14 studies for histologic grade 1 to 2 versus
histologic grade 3 to 4, adenocarcinoma versus squamous
cell carcinoma, with LN metastasis versus without LN me-
tastasis for MMP-7 protein expression were symmetrical,
and Egger's test showed no publication bias (all P >0.05)
(Figure 5).
Discussion
Our meta-analysis results reveal a strong link between
MMP-7 overexpression and lung cancer progression. The
Figure 3 Subgroup analyses of the association between matrix metalloproteinase 7 (MMP-7) protein expression and the pathological
characteristics of lung carcinoma.
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Figure 4 Sensitivity analysis of the summary odds ratio coefficients for the association between matrix metalloproteinase 7 (MMP-7)
protein expression and the pathological characteristics of lung carcinoma.
Figure 5 Funnel plot of publication biases for the association between matrix metalloproteinase 7 (MMP-7) protein expression and the
pathological characteristics of lung carcinoma.
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sociation between MMP-7 and TMN stages, histologic
grade and LN metastasis of lung cancer but not between
MMP-7 and histology. Glandular and ductal epithelial
cells mainly produce MMP-7. MMP-7, when overex-
pressed in tumor cells, plays a central role in the progres-
sion of many tumors such as gastric cancer, esophageal
cancer, colorectal cancer, liver cancer, renal cancer and
pancreatic cancer and is a reliable indicator for high recur-
rence of cancer, poor prognosis and low rate of survival
[42-44]. MMP-7 overexpression is reported to be associ-
ated with the TNM stage, histologic grade and LN metas-
tasis of lung cancer. Our analysis shows that MMP-7
expression is higher in the III-IV stage than in the I-II
stage and is overexpressed to a greater degree in the 1 to 2
histologic grade than in the 3 to 4 histologic grade, sug-
gesting an important role of MMP-7 in the progression of
lung cancer [17,24]. Our multiple levels of analysis showed
a consistent association between MMP-7 protein ex-
pression and LN metastasis, which suggest that MMP-7
mediated degradation of basement membrane could
play a central role in lymphatic permeation and infiltra-
tive growth of lung tumors [36]. MMP-7 overexpression
could also regulate the proliferation of lung cancers
through activation of EGFR and the production of
mature HB-EGF to activate the receptor ErbB4. Wnt1 is
involved in the regulation of MMP-7 expression, and
therefore, Wnt signaling pathway plays a significant role in
the lung cancers [17]. MMP-7 activity related to E-cadherin
shedding could drive the accumulation of β-catenin in lung
cancers overexpressing MMP-7, leading to the activation of
multiple pathways involving dysregulated functions of both
extracellular and intracellular components [45]. Thus, we
conclude that MMP-7 overexpression is tightly linked with
the TMN stages, histologic grade and LN metastasis of lung
cancer, due to its direct ability for ECM degradation, tissue
remodeling and tumor cell proliferation, and also indirectly
influence lung cancer metastasis by the abnormal activation
of the Wnt signaling pathway and the accumulation of
β-catenin. Consistent with our analysis, Safranek et al.
found higher MMP-7 protein expression in both adeno-
carcinoma and squamous lung carcinoma compared with
benign lung tissue [13].
The age-stratified analysis demonstrated that the
associations between histologic grade, LN metastasis,
and MMP-7 overexpression are significant in lung can-
cer patients irrespective of age, while the association
between TNM stages and MMP-7 overexpression is
observed to be significant only in lung cancer patients
under age 60. Thus, the MMP-7 overexpression pat-
tern more closely reflects the tumor behavior than the
current staging systems, indicating the role of MMP-7
as a potent biomarker for the pathological features of
lung cancer.Our meta-analysis sheds light on the association
between MMP-7 protein expression and lung cancer
progression, using a comprehensive and systematic
approach based on previously published studies. All
included studies in our meta-analysis were high-grade.
While our meta-analysis has uncovered the advantages of
MMP-7 based clinical evaluation, there does exist some
limitations in the current meta-analysis. First, although we
performed a methodological assessment of studies to
avoid selection biases, there was significant heterogeneity
among the 14 studies that may be attributed to the fact
that the technique for detecting MMP-7 was not uniform
among studies, or among the different ethnic backgrounds
and lifestyles. Second, original data was unavailable for the
present analysis, which might have had an impact on the
stability of our overall results. Third, we could also not
perform more precise calculation of ORs and further
stratified analysis of potential heterogeneity that may
affect the results. Fourth, some studies lacked information
on age and detection method, and we examined one
tumor biomarker expression in lung cancer cell lines.
Therefore, the results of this study should act as a reliable
primer for further focused studies, through prospective
randomized controlled trials with integrity of information
and more credible markers, to confirm our present finding
and allow us to move toward clinical applications based
on MMP-7.Conclusions
In summary, an increased expression of MMP-7 was
found in the present meta-analysis to be strongly asso-
ciated with advanced TNM stage, histologic grade, and
aggressive LN metastasis in lung cancer patients. Based
on our results, we propose that a MMP-7 specific in-
hibitor may prevent and treat invasion and metastasis
of lung cancer. However, based on the above limita-
tions, further in-depth studies are recommended to
confirm our findings and to understand the exact role
of MMP-7 in lung cancer progression.
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